Do Traders Think Northwest Biotherapeutics Inc (NWBO) Can Keep Climbing Friday?

The market has been high on Northwest Biotherapeutics Inc (NWBO) stock recently. NWBO gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Northwest Biotherapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NWBO!

See Full NWBO Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With NWBO Stock Today?

Northwest Biotherapeutics Inc (NWBO) stock is trading at $1.18 as of 2:52 PM on Friday, Nov 18, a gain of $0.14, or 13.46% from the previous closing price of $1.04. The stock has traded between $1.12 and $1.27 so far today. Volume today is more active than usual. So far 9,804,367 shares have traded compared to average volume of 2,110,606 shares. To see InvestorsObserver's Sentiment Score for Northwest Biotherapeutics Inc click here.

More About Northwest Biotherapeutics Inc

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration. Click Here to get the full Stock Report for Northwest Biotherapeutics Inc stock.